News Releases

Date	Title and Summary	View
Mar 06, 2018	Johnson & Johnson to Participate in Barclays Global Healthcare Conference NEW BRUNSWICK, N.J. , March 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Tuesday, Mar. 13 , at the Loews Miami Beach Hotel , Miami , FL. Joaquin Duato , Executive Vice President, Worldwide Chairman, Pharmaceuticals will
Mar 01, 2018	Johnson & Johnson Vision Announces New Digital Platform for Eye Care Professionals JACKSONVILLE, Fla. , March 1, 2018 /PRNewswire/ -- Johnson & Johnson Vision today announced the U.S. launch of JNJVISIONPRO.COM , a digital platform that delivers online learning, patient education materials, practice resources and connected commerce - all aimed at streamlining and simplifying the
Feb 20, 2018	Johnson & Johnson to Participate in Cowen 38th Annual Healthcare Conference NEW BRUNSWICK, N.J. , Feb. 20, 2018 /PRNewswire/ -- Johnson & Johnson ( NYSE : JNJ) will participate in the Cowen 38th Annual Healthcare Conference on Tuesday, Mar. 13 , at The Boston Marriott Copley Place , Boston . Ashley McEvoy , Company Group Chairman, Consumer Medical Devices will represent
Feb 20, 2018	Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics
Feb 16, 2018	Johnson & Johnson Consumer Presents New Scientific Research At 2018 American Academy of Dermatology Annual Meeting SKILLMAN, N.J. , Feb. 16, 2018 /PRNewswire/ -- Reinforcing leadership in scientifically-driven skincare, Johnson & Johnson Consumer Inc. will present eight Scientific Posters at this year's American Academy of Dermatology (AAD) Annual Meeting in San Diego , CA. The new research spans priority
Feb 15, 2018	Health Canada Approves New Indication for ZYTIGA®* (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer ZYTIGA ® , used in combination with prednisone and androgen deprivation therapy, was shown to reduce the risk of death by 38 per cent 1 TORONTO , Feb. 15, 2018 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced Health Canada's approval of ZYTIGA ® (abiraterone
Feb 14, 2018	ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 08, 2018	Johnson & Johnson to Participate in the 2018 CAGNY Conference NEW BRUNSWICK, N.J. , Feb. 8, 2018 /PRNewswire/ -- Johnson & Johnson ( NYSE : JNJ) will participate in the 2018 CAGNY Conference on Thursday, Feb. 22 , at The Boca Raton Resort , Boca Raton , FL. Jorge Mesquita , Executive Vice President, Worldwide Chairman, Consumer and Alison Lewis , Chief
Feb 08, 2018	Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio NEW BRUNSWICK, N.J. , Feb. 8, 2018 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson ( NYSE : JNJ) will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN data for the investigational compound apalutamide in non-metastatic castration-resistant prostate
Feb 08, 2018	Janssen Submits Marketing Authorisation Application for Apalutamide to Treat Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer